Previous studies about the role of CCL5 in PC are not inconsistent, a clinical trial suggested that low circulating levels of CCL5 predicted prolonged overall survival for PC patients receiving chemoradiotherapy (32). This evidence concerns the gene CCL5 and pachyonychia congenita.